A Phase I Randomized Single-blind Placebo-controlled 2-part Study to Assess the Safety, Tolerability and Pharmacokinetics and Pharmacodynamics of AZD0284 Following Single and Multiple Ascending Dose Administration to Healthy Subjects
Phase of Trial: Phase I
Latest Information Update: 19 Jun 2017
At a glance
- Drugs AZD 0284 (Primary)
- Indications Plaque psoriasis
- Focus Adverse reactions
- Sponsors AstraZeneca
- 13 Jun 2017 Status changed from recruiting to completed.
- 10 Feb 2017 Planned End Date changed from 1 Jun 2017 to 1 May 2017.
- 10 Feb 2017 Planned primary completion date changed from 1 Jun 2017 to 1 May 2017.